Quality-adjusted life year weights among elderly patients with heart failure

European Journal of Heart Failure

Volumn 10, Issue 10, 2008, Pages 1033-1039

  Alehagen, Urban ^a   Rahmqvist, Mikael ^b   Paulsson, Thomas ^c   Levin, Lars Åke ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Elderly patients; Health related quality of life; Heart failure; QALY

Indexed keywords

AGED; ARTICLE; CARDIOLOGY; DISEASE CLASSIFICATION; FEMALE; FUNCTIONAL STATUS; GERIATRIC PATIENT; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEDICAL SPECIALIST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; SHORT FORM 36; TIME TRADE OFF;

AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HEALTH STATUS INDICATORS; HEALTH SURVEYS; HEART FAILURE; HUMANS; MALE; PSYCHOLOGICAL TESTS; PSYCHOMETRICS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SWEDEN;

EID: 53449095756     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.07.015     Document Type: Article

References (34)

1. Rich M.W. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 45 8 (1997) 968-974
2. Weintraub W.S., Cole J., and Tooley J.F. Cost and cost-effectiveness studies in heart failure research. Am Heart J 143 4 (2002) 565-576
3. Stewart A.L., Greenfield S., Hays R.D., Wells K., Rogers W.H., Berry S.D., et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 262 7 (1989) 907-913
4. Cleland J.G. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 19 (1998) 32-39 Suppl P
5. Ryden-Bergsten T., and Andersson F. The health care costs of heart failure in Sweden. J Intern Med 246 3 (1999) 275-284
6. Weinstein M.C., and Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296 13 (1977) 716-721
7. Neumann J.V.M.O. Theory of games and economic behavoiur (1947), Princeton University Press, London
8. Torrance G.W. Measurement of health state utilities for economic appraisal. J Health Econ 5 1 (1986) 1-30
9. Brooks R.G., Jendteg S., Lindgren B., Persson U., and Bjork S. EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise. Health Policy 18 1 (1991) 37-48
10. Roberge R, Berthelot JM, Wolfson M. The Health Utility Index: measuring health differences in Ontario by socioeconomic status. Health Rep 1995; 7(2):25-32(Eng); 29-37(Fre).
11. van Hout B.A., Wielink G., Bonsel G.J., and Rutten F.F. Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model. Pharmacoeconomics 3 5 (1993) 387-397
12. Michel B.C., Al M.J., Remme W.J., Kingma J.H., Kragten J.A., van Nieuwenhuizen R., et al. Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands. Eur Heart J 17 5 (1996) 731-740
13. Vermeer F., Simoons M.L., de Zwaan C., van Es G.A., Verheugt F.W., van der Laarse A., et al. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands. Br Heart J 59 5 (1988) 527-534
14. Simoons M.L., Vos J., and Martens L.L. Cost-utility analysis of thrombolytic therapy. Eur Heart J 12 6 (1991) 694-699
15. Levin L.A., and Jonsson B. Cost-effectiveness of thrombolysis-a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J 13 1 (1992) 2-8
16. O'Brien B.J., Buxton M.J., and Patterson D.L. Relationship between functional status and health-related quality-of-life after myocardial infarction. Med Care 31 10 (1993) 950-955
17. Gorkin L., Follick M.J., Geltman E., Hamm P., Sollano J., Sylvia S., et al. Quality of life among patients post-myocardial infarction at baseline in the Survival and Ventricular Enlargement (SAVE) trial. Qual Life Res 3 2 (1994) 111-119
18. Tsevat J., Goldman L., Lamas G.A., Pfeffer M.A., Chapin C.C., Connors K.F., et al. Functional status versus utilities in survivors of myocardial infarction. Med Care 29 11 (1991) 1153-1159
19. Glasziou P.P., Bromwich S., and Simes R.J. Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality Trial. Med J Aust 161 9 (1994) 532-536
20. Lewis E.F., Johnson P.A., Johnson W., Collins C., Griffin L., and Stevenson L.W. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 20 9 (2001) 1016-1024
21. Kirsch J., and McGuire A. Establishing health state valuations for disease specific states: an example from heart disease. Health Econ 9 2 (2000) 149-158
22. Alehagen U., Eriksson H., Nylander E., and Dahlström U. Heart failure in the elderly. Characteristics of a Swedish primary health care population. Heart Drug 2 (2002) 211-220
23. Kumar A., Choudhary G., Antonio C., Just V., Jain A., Heaney L., et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 142 3 (2001) 512-515
24. McHorney C.A., and Ware Jr. J.E. Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31 3 (1993) 247-263
25. Choy A.M., Darbar D., Lang C.C., Pringle T.H., McNeill G.P., Kennedy N.S., et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 72 1 (1994) 16-22
26. Jensen-Urstad K., Bouvier F., Hojer J., Ruiz H., Hulting J., Samad B., et al. Comparison of different echocardiographic methods with radionuclide imaging for measuring left ventricular ejection fraction during acute myocardial infarction treated by thrombolytic therapy. Am J Cardiol 81 5 (1998) 538-544
27. van Royen N., Jaffe C.C., Krumholz H.M., Johnson K.M., Lynch P.J., Natale D., et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 77 10 (1996) 843-850
28. Morimoto T., and Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 12 2 (2002) 160-178
29. Post P.N., Stiggelbout A.M., and Wakker P.P. The utility of health states after stroke: a systematic review of the literature. Stroke 32 6 (2001) 1425-1429
30. Rowley P.T., Loader S., and Kaplan R.M. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Am J Hum Genet 63 4 (1998) 1160-1174
31. Alehagen U., Lindstedt G., Levin L.A., and Dahlstrom U. The risk of cardiovascular death in elderly patients with possible heart failure. Results from a 6-year follow-up of a Swedish primary care population. Int J Cardiol 100 1 (2005) 17-27
32. Alehagen U., Lindstedt G., Levin L.A., and Dahlstrom U. Risk of cardiovascular death in elderly patients with possible heart failure B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population. Int J Cardiol 100 1 (2005) 125-133
33. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 10 (1992) 669-677
34. Swedberg K., and Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 62 2 (1988) 60A-66A